
A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma
Keywords: Advanced urothelial cancer; Antiangiogenic therapy; CD105; Immune subsets; Metastatic urothelial cancer; Urothelial cancer;